Corneal Neovascularization
Conditions
Keywords
bevacizumab, cornea, neovascularization
Brief summary
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.
Detailed description
To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization. Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.
Interventions
DRUGBevacizumab
subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
Sponsors
Instituto de Olhos de Goiania
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Corneal Neovascularization * Stable lesion
Exclusion criteria
* Diabetes * Autoimmune diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Effect of Bevacizumab on Corneal Neovascularization | Compare the results | Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography |
Outcome results
None listed